Showing 51-60 of 77 results for "".
Skin Checks and Patient Education on Actinic Keratoses
https://practicaldermatology.com/topics/skin-cancer-photoprotection/skin-checks-and-patient-education-on-actinic-keratoses/20132/During skin checks, it's important for dermatologists to educate patients, especially younger ones, about the extent of sun damage and the benefits of field treatments. Anthony Rossi, MD and Vishal Patel, MD discuss their approaches.Know Your Lesions: The Many Variations of Seborrheic Keratosis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/know-your-lesions-the-many-variations-of-seborrheic-keratosis/20679/SKs are benign lesions that may be removed for medical or aesthetic reasons. It's essential to distinguish SKs from malignant lesions.New Options for the Treatment of Extensive Seborrheic Keratosis
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-options-for-the-treatment-of-extensive-seborrheic-keratosis/23129/A compounded formulation with an adhesive vehicle offers an alternative to procedures for this common patient complaint.Overcoming Real and Perceived Challenges in Medical Management of Actinic Keratoses
https://practicaldermatology.com/topics/general-topics/overcoming-real-and-perceived-challenges-in-medical-management-of-actinic-keratoses/21845/Everyone from prescribers to patients to pharmacists plays a role in the successful incorporation of medical AK management.Medical Management of Actinic Keratoses and Non- Melanoma Skin Cancer: Disease Progression and Mechanisms of Action of Therapy
https://practicaldermatology.com/topics/general-topics/medical-management-of-actinic-keratoses-and-non--melanoma-skin-cancer-disease-progression-and-mechanisms-of-action-of-therapy/21553/The approach to treatment may be shifting from targeting the lesions we see to addressing an underlying pathology.Advances in Treating NMSC
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advances-in-treating-nmsc/18742/Dr. Goldenberg discusses the benefits of timed sequential therapy using two modalities — destructive therapy followed by field therapy — for actinic keratoses. He also talks about treatment options for advanced basal cell carcinoma, squamous cell carcinoma, and merkel cell carcinoma.Chemoprevention Strategies for AK Patients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/chemoprevention-strategies-for-ak-patients/18822/Neal Bhatia, MD, Chief Medical Editor of Practical Dermatology®, provides strategies for treating actinic keratoses, as well as for prevention and management. He discusses the importance of sun protection and photodamage prevention, and says the key to treatment and maintenance is combination therapNew Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million d- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved t